Page last updated: 2024-08-24

milnacipran and duloxetine

milnacipran has been researched along with duloxetine in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Morphy, R; Rankovic, Z1
Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Jovic, F; Mesleh, M; Phan, K; Tamiya, J; Vickers, T; Zhang, M1
Bradbury, MJ; Chen, C; Dyck, B; Fleck, BA; Foster, AC; Grey, J; Johns, M; Jovic, F; Li, B; Madan, A; O'Brien, J; Pick, RR; Saunders, J; Tamiya, J; Tran, JA; Vickers, T; Wen, J; Zhang, M1
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC1
Chang, R; Church, TJ; Jaw-Tsai, S; Martin, WJ; Saito, DR; Smith, JA; Stangeland, EL; Van Dyke, PM; Van Orden, LJ1
Badescu, VO; de Frutos, O; de la Puente, ML; Ding, C; Dreyfus, N; Filla, SA; Fynboe, K; Gernert, DL; Heinz, BA; Hemrick-Luecke, SK; Iyengar, S; Johansson, AM; Johnson, KW; Johnson, MP; Joshi, E; López, P; Love, PL; Martin, LJ; Masquelin, T; McCoy, MJ; Mendiola, J; Morrow, D; Muhlhauser, M; Myers, JK; Pascual, G; Perun, TJ; Pfeifer, LA; Phebus, LA; Richards, SJ; Rincón, JA; Seest, EP; Shah, J; Shaojuan, J; Simmons, RM; Stephenson, GA; Thomas, CE; Thompson, LK; Tromiczak, EG; Walter, MW; Weber, WW; Zarrinmayeh, H1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

2 review(s) available for milnacipran and duloxetine

ArticleYear
Designed multiple ligands. An emerging drug discovery paradigm.
    Journal of medicinal chemistry, 2005, Oct-20, Volume: 48, Issue:21

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors

2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for milnacipran and duloxetine

ArticleYear
Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Feb-15, Volume: 18, Issue:4

    Topics: Acetamides; Alkylation; Amides; Cyclopropanes; Indoles; Milnacipran; Models, Molecular; Molecular Conformation; Nuclear Magnetic Resonance, Biomolecular; Stereoisomerism; Structure-Activity Relationship; Vesicular Monoamine Transport Proteins

2008
Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.
    Journal of medicinal chemistry, 2008, Nov-27, Volume: 51, Issue:22

    Topics: Administration, Oral; Animals; Biological Availability; Caco-2 Cells; Crystallography, X-Ray; Cyclopropanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Microsomes, Liver; Milnacipran; Models, Molecular; Molecular Structure; Molecular Weight; Neuralgia; Norepinephrine Plasma Membrane Transport Proteins; Pain Measurement; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Stereoisomerism; Structure-Activity Relationship

2008
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility

2010
A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships.
    Bioorganic & medicinal chemistry letters, 2013, Mar-01, Volume: 23, Issue:5

    Topics: Animals; Crystallography, X-Ray; Disease Models, Animal; Humans; Nerve Tissue Proteins; Neurotransmitter Uptake Inhibitors; Norepinephrine; Pain; Pyrrolidines; Rats; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship

2013
Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor.
    ACS medicinal chemistry letters, 2013, Jun-13, Volume: 4, Issue:6

    Topics:

2013